Skip to main content
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
Lyrea avatar

Not yet reviewed — this article is pending editorial review by Lyrea.

ALEPH-2

ALEPH-2 molecule structureALEPH-2 molecule structure
2,5-Dimethoxy-4-ethylthioamphetamine
4-Ethylthio-2,5-dimethoxyamphetamine

ALEPH-2 is a rare psychedelic of the substituted amphetamine and phenethylamine classes, belonging to both the Aleph series and DOx family. First described by Alexander Shulgin in 1978 and later documented in his 1991 book PiHKAL, it functions as the DOx analogue of 2C-T-2.citation needed It is reported to be potent and to produce long-lasting, highly visual experiences. Very little human use data is available.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~3 mg
Light3-5 mg
Moderate5-7 mg
Strong7-8 mg
Heavy8+ mg

Suspected to be potent, with substantial individual variation in response; one report described strong effects at 4 mg while another described only a bare threshold at 8 mg.

Duration

Onset40-120 minutes
After Effects12-24 hours
Total6-18 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

ALEPH-2 produces a long-lasting psychedelic state that is notably unpredictable in both potency and character. Responses vary dramatically between individuals and occasions: one report describes 4 mg producing incapacitation with a fetal position, hours of relative hibernation, and substantial amnesia, while another describes 8 mg yielding only a bare threshold with slight lightheadedness. Visual effects show the same inconsistency, ranging from almost entirely absent to extraordinary distortions and near-hallucinatory illusions. Effects can continue climbing for two hours or more, with residual shakiness, tremor, and disturbed sleep persisting well into the night.

Physical

The body load includes mental and physical stimulation, restlessness, muscle tension, and a sensation of physical warmth alongside sweating and chills. The offset is marked by residual shakes, muscular tremor, muscular weakness, jaw tension, and insomnia.

Autonomic

Pupil dilationAppetite suppression

Stimulation

Uncomfortable

Muscle tension

Cognitive

The headspace can include euphoria, enhanced empathy, insight, and a softening of the ego, but also confusion and a markedly solipsistic quality at strong doses, in which the user feels like the center of their world and distrusts that others share the same reality. Interpretive shifts can render mundane environments magical or strip expected wonder from novel ones.

Confusion

Emotional

Visual

Visual effects are highly variable between experiences, from almost none at 8 mg to extraordinary distortion and illusion at 5 mg.

Color enhancement

Auditory

Auditory enhancement

Tactile

Tactile enhancement

See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)

Pharmacology

Pharmacodynamics

ALEPH-2 acts as a serotonin 5-HT2 receptor agonist.1 It also functions as a weak monoamine oxidase inhibitor, with substantially greater potency at MAO-A (IC50 3,200 nM) compared to MAO-B (IC50 >100,000 nM).2

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Cross Tolerance

Serotonergic psychedelics (LSD, psilocybin, mescaline, DOx compounds), Other 5-HT2A agonists

Harm Potential

Toxicity

Musculoskeletal

Muscle tension, considerable muscular tremor, and marked muscular weakness have been reported during intoxication, sometimes persisting for hours after the peak effects subside.

Psychosis Risk

Confusion has been reported as an acute effect. One case at 4 mg produced substantial amnesia and a state of relative hibernation lasting several hours, though explicit psychotic symptoms have not been documented.citation needed

History & Culture

ALEPH-2 was first introduced to the scientific literature by Alexander Shulgin in 1978 as part of his systematic exploration of phenethylamine derivatives.citation needed The compound belongs to the Aleph series, a family of sulfur-substituted psychedelic amphetamines that Shulgin developed and…

Legality

By Country

Illegal2
United States flagUnited StatesIllegal
Netherlands flagNetherlandsIllegal (analog/blanket ban)

References

Source Pages

  1. Bluelight: ALEPH-2 4.2mg trip report
  2. Bluelight: ALEPH-2 discussion thread
  3. Bluelight: community caution on sulfur-substituted phenethylamines (DOT/ALEPH thread)
  4. Bluelight: The Big and Dandy DOT/ALEPH-1 Thread
  5. DrugBank: 2,5-Dimethoxy-4-ethylthioamphetamine
  6. Erowid ALEPH-2 Experience: The Continuum Hypothesis
  7. Isomer Design (TiHKAL/PiHKAL)
  8. PiHKAL #4 ALEPH-2 (isomerdesign mirror)
  9. PiHKAL.info - ALEPH-2 Chemical Data
  10. Wikipedia

Citations

  1. Claudio Acuña-Castillo, Cecilia Scorza, Miguel Reyes-Parada, Bruce K. Cassels, & J.Pablo Huidobro-Toro. (2000). ALEPH-2, a suspected anxiolytic and putative hallucinogenic phenylisopropylamine derivative, is a 5-HT2a and 5-HT2c receptor agonist. Life Sciences. https://doi.org/10.1016/s0024-3205(00)00906-11
  2. Miguel Reyes-Parada, Patricio Iturriaga-Vasquez, & Bruce K. Cassels. (2019). Amphetamine Derivatives as Monoamine Oxidase Inhibitors. Front Pharmacol, 10. https://doi.org/10.3389/fphar.2019.015901
  3. Opiumwet. wetten.overheid.nl (n.d.). https://wetten.overheid.nl/BWBR0001941/2025-07-011
  4. Electronic Code of Federal Regulations. ecfr.gov (n.d.). https://www.ecfr.gov/api/versioner/v1/full/2026-08-13/title-21.xml?part=130012345
  5. Drug Enforcement Administration, Diversion Control Division. deadiversion.usdoj.gov (n.d.). https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf12

Further Reading

  1. Acuna-Castillo et al., 2002 - Potency and efficacy at 5-HT2A/2C across PIAs (BJP)
  2. Acuna-Castillo et al., 2002 - Potency and efficacy at 5-HT2A/2C receptors
  3. PiHKAL Mirror: Pihkal
  4. PubChem: 2,5-Dimethoxy-4-ethylthioamphetamine
  5. Reyes-Parada et al., 2019 - Review of amphetamine derivatives as MAO inhibitors

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed — this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes7 human edits · latest

Times are UTCNewest first

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the ALEPH-2 article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.